In this episode, Lucas and Luna explore how quantum computing is being used to simulate molecular interactions for drug clinical trials. They focus on a specific case: a partnership between pharmaceutical company Roche and quantum computing firm IonQ. Using quantum algorithms, the team simulated the binding affinity of a cancer drug candidate to its target protein, reducing the initial screening time from months to weeks. The hosts explain the technical breakthrough—quantum chemistry simulations using variational quantum eigensolvers—and discuss the implications for clinical trial timelines and costs. They also address current limitations, including qubit coherence and error rates, and why pharma companies are investing heavily in this technology now. The episode is grounded in real numbers: a 3x speedup in lead candidate identification and a potential $1 billion savings in drug development costs per successful drug. No hype, just a clear look at where quantum's impact is already measurable.

#QuantumComputing #DrugDiscovery #ClinicalTrials #Roche #IonQ #QuantumChemistry #Pharmaceuticals #Technology #Business #Podcast #FexingoBusiness #BusinessPodcast #TechPodcast #QuantumSimulation #VQE #DrugDevelopment #HealthcareTech #QuantumAlgorithms

Keep every episode free: buymeacoffee.com/fexingo